SEC 13F Intelligence

Mpm Bioimpact LLC / CGEM

Mpm Bioimpact LLC’s Cullinan Therapeutics Inc Position

Does Mpm Bioimpact LLC own Cullinan Therapeutics Inc (CGEM)? Yes — 7.65M shares worth $109M (+8.39% of its 13F portfolio) as of Q1 2026.

Position Value
$109M
Q1 2026
Shares
7.65M
% of Portfolio
+8.39%
Quarters Held
21
currently held

Position History CGEM

Reported value by quarter
Q1 ’21: $330MQ1 ’21Q2 ’21: $204MQ3 ’21: $173MQ4 ’21: $118MQ4 ’21Q1 ’22: $80MQ2 ’22: $98MQ3 ’22: $98MQ3 ’22Q4 ’22: $81MQ1 ’23: $78MQ2 ’23: $82MQ2 ’23Q3 ’23: $69MQ4 ’23: $78MQ1 ’24: $130MQ1 ’24Q2 ’24: $133MQ3 ’24: $128MQ4 ’24: $93MQ4 ’24Q1 ’25: $58MQ2 ’25: $58MQ3 ’25: $45MQ3 ’25Q4 ’25: $79MQ1 ’26: $109Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20267.65M$109M+8.39%
Q4 20257.65M$79M+9.06%
Q3 20257.65M$45M+7.42%
Q2 20257.65M$58M+9.98%
Q1 20257.65M$58M+9.95%
Q4 20247.65M$93M+13.23%
Q3 20247.65M$128M+19.21%
Q2 20247.65M$133M+20.73%
Q1 20247.65M$130M+20.95%
Q4 20237.65M$78M+18.23%
Q3 20237.65M$69M+18.48%
Q2 20237.65M$82M+16.57%
Q1 20237.65M$78M+20.33%
Q4 20227.65M$81M+20.93%
Q3 20227.65M$98M+23.22%
Q2 20227.65M$98M+27.24%
Q1 20227.65M$80M+21.49%
Q4 20217.65M$118M+21.51%
Q3 20217.65M$173M+26.78%
Q2 20217.91M$204M+33.48%
Q1 20217.91M$330M+41.43%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Mpm Bioimpact LLC’s full portfolio or all institutional holders of CGEM.